The IPO Market's Late-July Inflection Point: SpaceX's $123B Lockup Cliff Meets a Biotech Issuance Wave

The IPO Market’s Late-July Inflection Point

The US IPO market enters the final week of July 2026 at a structural crossroads. Three forces are converging simultaneously: SpaceX’s historic lockup schedule begins unlocking in early August, potentially flooding the market with $123 billion in newly tradable shares; a biotech IPO wave is accelerating into the second half; and the SEC is quietly reshaping the market’s plumbing with a proposed rescission of the trade-through rule and an extended delay of tick-size reductions. Each of these developments would matter on its own. Together, they define the supply-and-structure backdrop for the remainder of 2026.

SpaceX’s Staggered Lockup: A $123B Supply Test

SpaceX went public on June 11, 2026, raising $75 billion at $135 per share on Nasdaq under the ticker SPCX — the largest IPO in US history, commanding a valuation above $2 trillion at listing.^[1][2] Less than 5% of the company’s total shares were released into public float at launch. Rather than the standard 180-day lockup, SpaceX structured a staggered release: tranches of roughly 7% unlock at days 70, 90, 105, 120, and 135 after the IPO.^[2]

The first major wave — between 20% and 30% of total shares — is set to land approximately two trading days after the company reports Q2 earnings, likely in early August. A second tranche of about 28% follows after Q3 earnings. By December 8, 2026, when the full 180-day period concludes, roughly 40% of all SpaceX shares will be freely tradable. Elon Musk’s shares carry a 366-day lockup, restricting his sales until approximately June 2027.^[2]

The supply math is already pressuring the stock. As of mid-July, SPCX was trading in the $124 to $135 range — below the $135 IPO price and approximately 49% below its post-listing high.^[2] The first unlock lands right after Q2 earnings, meaning the stock will simultaneously digest financial results and absorb a massive supply increase from roughly 911.5 million shares valued at approximately $123 billion at recent prices.^[2]

This is not a typical lockup expiry. The sheer scale — $123 billion in shares entering the float against a stock already trading below its IPO price — makes this one of the largest supply-overhang events in market history. Whether the market can absorb it without a material repricing depends on demand from index funds, institutional allocators, and the retail base that participated in the IPO.

SK hynix: The Foreign-Listing Benchmark

Two weeks before Scribe Therapeutics’ debut, SK hynix completed its Nasdaq listing on July 10, 2026, raising $26.5 billion — the largest foreign IPO in US history.^[3] The Korean memory-chip giant sold 177.9 million American Depositary Shares at $149 each, with each ADS representing one-tenth of a common share.^[3] The ADRs opened at $170, 14% above the offer price, in a strong first-day reception.^[3]

The SK hynix deal surpassed the prior record for a foreign company’s US share sale and underscored the depth of demand for AI-exposed listings.^[3] It also set a benchmark: any subsequent large-scale listing — or lockup-driven supply event — will be measured against the demand absorption the SK hynix deal demonstrated.

Biotech IPOs: Open Window, Selective Terms

While SpaceX and SK hynix dominated headlines, the biotech sector has quietly become the standout performer of the 2026 IPO class. Biotech and pharma IPOs in the US have returned 55% on average year-to-date, while the broader IPO market has lost 4.4%.^[4] The sector has raised approximately $5 billion from stock offerings in 2026.^[4]

The pipeline is deepening. BPIQ recorded 15 biotech IPOs in H1 2026, up 114% from seven in H1 2025 — the highest first-half total since 2021, though still below the 2020/2021 peak.^[4] The S-1 queue continues to grow, with Jaguar Health and Vogenx filing in mid-July.^[4]

Scribe Therapeutics (Nasdaq: SCTX) crystallized the trend on July 23–24, pricing an upsized IPO at $15 per share — the high end of its $13–$15 range — and raising $129 million by offering 8.6 million shares, 1.4 million more than originally anticipated.^[5] The nine-year-old company, co-founded by CRISPR pioneer Jennifer Doudna, is developing in vivo CRISPR therapies for cardiovascular disease, with its lead program targeting high cholesterol via PCSK9 and Lp(a) pathways.^[5][6] The company also entered a concurrent private placement with Sanofi.^[6] Endpoints News characterized the deal as the start of a “second-half IPO spree” for biotech.^[4]

The window, however, remains selective. Tarsier Pharma’s approximately $45 million NYSE American listing shows the window stays open only for companies with genuinely differentiated, late-stage pipelines.^[4] The contrast between the biotech sector’s 55% average return and the broader IPO market’s -4.4% decline suggests investors are discriminating by quality rather than rotating broadly into new issues.^[4]

The Performance Divide: Not All New Stocks Are Equal

The YTD IPO statistics reveal a sharp divergence. Renaissance Capital reports 87 IPOs priced in 2026 through late July, a -26.9% decline from the same period last year, but total proceeds of $142.5 billion — a +679.4% surge driven almost entirely by SpaceX’s $75 billion and SK hynix’s $26.5 billion deals.^[1] Filing activity is up 10.1% to 153 filings, suggesting the pipeline for the remainder of the year is building.^[1]

The Renaissance IPO Index was up 30.3% year-to-date as of late June, more than triple the S&P 500’s 9.6% return.^[7] But that index-weighted performance masks significant dispersion among individual new listings:

^[1][3][2]

QumulusAI’s trajectory is a cautionary data point. The AI cloud infrastructure company completed a direct listing on July 16 and subsequently fell sharply — trading at approximately $7.16 as of July 24, down roughly 48% from its listing, despite an announced Nvidia GPU purchase and partnership.^[8] Standard Nuclear (STDN) has fallen 40.6% from its offer price.^[1] The biotech sector, by contrast, has been the consistent outlier to the upside.^[4]

Secondary Offerings: Magnolia’s $1.1B Capital Raise

New issuance is not limited to IPOs. Magnolia Oil & Gas Corporation (NYSE: MGY) priced a $1.1 billion equity offering on July 20, 2026, selling 46.3 million Class A shares at $23.75 per share, with underwriters fully exercising a 30-day option for an additional 6.9 million shares.^[9] J.P. Morgan, Goldman Sachs, Citi, Wells Fargo, and BofA led the syndicate.^[9] The proceeds are earmarked to fund the company’s WildFire acquisition.^[9]

Dyne Therapeutics (Nasdaq: DYN) also closed an upsized public offering on July 23, with underwriters fully exercising their option to purchase additional shares.^[10] Robin Energy (Nasdaq: RBNE) priced a smaller $3 million offering on July 24.^[10] The SEC’s EDGAR system shows multiple 424B5 prospectus filings active in July, indicating a steady flow of follow-on issuance across sectors.^[10]

Buyback Activity: A Partial Counterweight

On the other side of the supply equation, several companies announced or advanced buyback programs in July:

• Flagstar Bank (NYSE: FLG): Authorized a $250 million share repurchase program on July 24.^[11]
• Equinor: Commenced the third tranche of its 2026 buyback program on July 23, up to $1.125 billion.^[11]
• A.P. Møller-Mærsk: Ongoing buyback of up to DKK 6.3 billion (~$1 billion) over 12 months.^[11]
• Alimentation Couche-Tard: Renewed its share repurchase program on July 16.^[11]
• Wolters Kluwer: Regular buyback executions continued through July 22.^[11]

These programs collectively represent billions in demand-side pressure that partially offsets the supply from IPOs and secondaries — though none approaches the scale of the SpaceX lockup release.

SEC Market-Structure Shifts: Tick Sizes and the Trade-Through Rule

On June 11, 2026, the SEC took two significant market-structure actions. First, it extended temporary exemptive relief from the compliance dates for the tick-size reduction (Rule 612, which would establish a $0.005 minimum pricing increment for certain NMS stocks) and the access-fee cap reduction (Rule 610(c)) until the first business day of November 2027.^[12] The original amendments, adopted in September 2024, have now been delayed twice — first to November 2026, then to November 2027.^[12]

Second, the SEC proposed to rescind Rule 611 of Regulation NMS — the trade-through rule — along with Rule 610(e), the locked and crossed market provisions.^[12] Chairman Paul Atkins directed staff to prioritize a review of Rules 610(c) and 612 by year-end.^[12]

The trade-through rule, which requires trading centers to execute orders at the best available price across all venues, has been a cornerstone of US market structure since Reg NMS was adopted in 2005. Its proposed rescission — combined with the delayed tick-size reduction — represents the most significant market-structure reconsideration in two decades. The practical implications for IPO liquidity are indirect but real: changes to order-routing incentives and quoting increments affect how newly public stocks are traded, especially in the early days when price discovery is most fragile.

IPO Pipeline: What’s Coming

The filing pipeline points to a sustained pace of new listings through the remainder of 2026:

• Lyntris: A military defense technology roll-up, filed for an estimated $300 million IPO on July 23.^[1]
• Tarsier Pharma: A ~$45 million NYSE American listing, expected in August.^[13]
• EvoAir Holdings: A Malaysia-based HVAC system maker, doubling shares offered ahead of a $34 million US IPO.^[1]
• SPACs: 132 SPAC IPOs priced YTD in 2026 — the most in any sector — including Market Technology Acquisition ($200 million) and Pelican Acquisition II ($75 million), both priced July 24.^[1]

The Renaissance calendar shows two IPOs scheduled for next week, with Scribe Therapeutics as the sole pricing this week.^[13]

What to Watch Next

1. SpaceX Q2 earnings and first lockup tranche (early August): This is the single most important supply event on the near-term calendar. The stock is already trading below its $135 IPO price. If the first 20–30% tranche of unlock hits on schedule and the stock slides further, it could set a negative tone for the entire large-cap IPO class. Conversely, if earnings exceed expectations and the float absorbs the unlock without significant decline, it would validate the depth of demand for premium new issues.

2. Biotech IPO cadence: Scribe Therapeutics’ upsized, high-end pricing — plus the Sanofi private placement — sets a constructive template. The question is whether subsequent biotech filings (Jaguar Health, Vogenx, and others in the S-1 queue) price with similar terms or begin to show signs of investor fatigue. Watch the filing-to-pricing conversion rate and whether deal sizes shrink.

3. SEC trade-through rule comment period: The proposed rescission of Rule 611 is out for public comment. The industry response — from exchanges, market makers, and institutional investors — will shape the final rule. Any timeline for implementation could affect trading liquidity for newly listed stocks.

4. Magnolia Oil & Gas integration: The $1.1 billion equity raise funds the WildFire acquisition. Watch for deal closing and initial integration commentary, which will signal whether the capital raise was well-timed or dilutive at current prices.

5. QumulusAI and the direct-listing cautionary tale: At -48% from listing despite an Nvidia partnership, QMLS is a reminder that not every AI-adjacent listing finds a floor. If direct listings continue to struggle while traditional underwritten IPOs (especially in biotech) succeed, the market may continue to favor the latter path.

6. SPAC volume: 132 SPACs priced YTD is the highest count in any sector. If SPAC deal announcements accelerate, trust redemption rates will indicate whether sponsors can find targets in a market already saturated with new issues.